2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Molecular Testing, Profiling, Treatment Considerations, Therapy Sequence, Biological Therapies, Transplantation, (CAR)-T Cell Therapies, Non-Biological Therapies, Chemotherapy, Biological Processes, Pathogenesis, Genomics, Molecular Biology, Clinical Practice (Health Services and Quality), Diseases, Hemoglobinopathies, Sickle Cell Disease, Immunology, Immunodeficiency, Neutropenia, White Blood Cell Disorders, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, B Cell Lymphoma, T Cell Lymphoma, Aggressive Lymphoma, Research, AML, MDS, Clinical Research, Epidemiology, Health Outcomes Research, Real-World Evidence, Survivorship, Study Population, Human, Adult, Pediatric
PAPER

6052 Donor type for allogeneic hematopoietic stem cell transplantation in adults with acute lymphoblastic leukemia in first complete remission and persistent measurable residual disease: A study from the ALWP of the EBMT

Ryszard Swoboda, MD, PhD, Thibeault Ferhat Berland, PhD2, Raynier Devillier, PhD3, Hélène Labussière-Wallet4, Anna Grassi, MD5, Gesine Bug, MD6, Ibrahim Yakoub-Agha7, Matthias Stelljes8, Nathalie Dhedin, MD, PhD9, Urpu Salmenniemi10, Jan Vydra11, Francis Ayuk12, Thomas Schroeder13, Alexandros Spyridonidis14, Claude-Éric Bulabois15, Matthias Eder16, Cristina Castilla-Llorente, MD17, Stefan Schönland, MD, PhD18, Eva Wagner Drouet19, Igor Wolfgang Blau20, Sebastian Giebel, MD, PhD21, Jaime Sanz, MD, PhD22, Eolia Brissot, MD, PhD23
1 Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice Branch, Gliwice, Poland
2 Sorbonne University, Paris, France
3 Institut Paoli-Calmettes, Université Aix-Marseille, Marseille, France
4 Hospices Civils de Lyon, Pierre-Bénite, France
5 Azienda Socio Sanitaria Territoriale Ospedale Papa Giovanni XXIII, Bergamo, Italy
6 Goethe-Universitaet, Frankfurt Main, Germany
7 CHU de Lille, Universitè Lille, INSERM U1286, Infinite, Lille, France
8 University Hospital Münster, Münster, Germany
9 Saint Louis Hospital, Paris, France
10 HUCH Comprehensive Cancer Center, Helsinki, Finland
11 Institute of Hematology and Blood Transfusion, Prague, Czech Republic
12 University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany
13 Universitätsklinikum Essen, Essen, Germany
14 University of Patras, Medical School, Patras, Greece
15 CHU Grenoble Alpes-Universite Grenoble Alpes, Grenoble, France
16 Medizinische Hochschule, Hannover, Germany
17 Gustave Roussy Paris Cancer Campus, Villejuif, France
18 Universitätsklinikum Heidelberg, Heidelberg, Germany
19 Universitätsmedizin Mainz, Mainz, Germany
20 Campus Virchow-Klinikum, Berlin, Germany
21 Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice Branch, Gliwice, Poland
22 Hospital Universitari i Politècnic La Fe, Departament de Medicina Universitat de Valencia, Valencia, Spain
23 Hospital Saint-Antoine, Sorbonne University, Paris, France

Introduction: Allogeneic hematopoietic stem cell transplantation (alloHSCT) remains the standard post-consolidation therapy for adult patients with high-risk acute lymphoblastic leukemia (ALL) in first complete remission (CR1). However, with the advent of modern treatment strategies, particularly immunotherapy, the indications for transplantation are being redefined. Measurable residual disease (MRD) is one of the strongest prognostic factors in ALL, and its persistence after induction and consolidation therapy is associated with inferior outcomes and a high risk of relapse. Therefore, patients with persistent MRD in CR1 represent a key population in whom alloHSCT continues to play a crucial therapeutic role. Despite accumulating evidence, comparative data on outcomes according to donor type in adult patients with ALL in CR1 and persistent MRD remain limited.

Aims: To compare the outcomes of alloHSCT according to donor type (matched sibling donor [MSD], matched unrelated donor [MUD], mismatched unrelated donor [MMUD], and haploidentical donor [haploD]) in adult patients with ALL in CR1 and persistent MRD at transplantation.

Methods: This multicenter retrospective study was based on data from the European Society for Blood and Marrow Transplantation (EBMT) registry and included 916 adult patients with ALL who underwent alloHSCT in CR1 with persistent MRD between 2015 and 2023. Patients transplanted from an MSD (n=160), MUD (n=458), MMUD (n=132), or haploD (n=166) were included.

Results: B-cell, T-cell precursor, and mixed-phenotype ALL accounted for 79.8%, 11.9%, and 5.2% of cases, respectively; data were missing for 3.1% of patients. The median recipient/donor ages were 45.1/43.6, 49.5/30.8, 44.2/30.6, and 46.1/37.1 years in the MSD, MUD, MMUD, and haploD groups, respectively (recipient age, p=.09; donor age, p<.001). Female donor-to-male recipient transplantation was reported in 20.4%, 11.0%, 16.9%, and 25.5% of patients, respectively (p<.001). Myeloablative conditioning (MAC) was used in 75.3%, 84.9%, 83.3%, and 76.4% of patients, respectively (p=.014). The median follow-up was 3.3 years (95% confidence interval, 3-3.7 years). The 2-year overall survival (OS), leukemia-free survival (LFS), relapse incidence (RI), and non-relapse mortality (NRM) were 77.5%, 64.3%, 29.3%, and 6.4% in the MSD group; 70.2%, 57.3%, 26.0%, and 16.7% in the MUD group; 64.5%, 49.7%, 27.7%, and 22.6% in the MMUD group; and 75.6%, 66.6%, 17.5%, and 15.9% in the haploD group, respectively. The incidences of acute (grade II-IV) and chronic graft-versus-host disease (GVHD) were 30.1% and 30.8% in the MSD group, 32.6% and 29.3% in the MUD group, 38.6% and 32.7% in the MMUD group, and 39.3% and 35.4% in the haploD group, respectively.

In multivariable analysis, transplantation from an MSD, MUD, or MMUD was associated with a significantly higher risk of relapse compared with haploD transplantation (HR 2.25, p=.006; HR 1.81, p=.044; and HR 1.87, p=.045, respectively). MMUD transplantation was associated with inferior LFS (HR 1.69, p=.031), whereas MSD transplantation was associated with a lower risk of NRM (HR 0.24, p=.005) and grade II-IV acute GVHD (HR 0.50, p=.024) compared with haploD transplantation. MAC (HR 1.52, p=.039) and female donor-to-male recipient transplantation (HR 1.55, p=.007) were independent risk factors for grade II-IV acute GVHD. MAC was associated with a lower risk of relapse (HR 0.66, p=.022), whereas older recipient age (per 10-year increase) was associated with inferior OS (HR 1.20, p=.001), inferior LFS (HR 1.11, p=.014), and higher NRM (HR 1.36, p<.001).

Conclusions: Transplant outcomes differ significantly according to donor type in adult patients with ALL undergoing alloHSCT in CR1 with persistent MRD. Haploidentical transplantation is associated with a significantly lower risk of relapse than transplantation from MSD, MUD, or MMUD donors. Compared with haploD transplantation, MSD transplantation is associated with lower risks of NRM and grade II-IV acute GVHD, whereas MMUD transplantation is associated with inferior LFS.

Ryszard Swoboda, MD, PhD: No relevant conflicts of interest to declare.